LOOK AT ALL THE BENEFITS OF THIS ANNOUNCEMENT:
Endonovo today announced it has acquired the PEMF assets of Rio Grande Neurosciences, Inc. ("RGN" for $4.5 million and settled its lawsuit concerning RGN's termination of the binding letter agreement to acquire RGN dated July 8, 2016.
RGN paid $150,000 to Endonovo Therapeutics
Endonovo to Fund All Currently Planned and Future Clinical Trials for Traumatic Brain Injury, Post-Concussion Syndrome, Stroke and Other Central Nervous System Disorders
ADDITIONAL SHARE HOLDER BENEFITS:
Endonovo believes settling the case at this time is in the best interest of all parties, and its acquisition of RGN's PEMF assets could result in substantial benefit to its shareholders.
27 MORE PATENTS:
The PEMF assets includes a portfolio of intellectual property, including 27 issued patents with foreign patent protection covering the therapeutic use of PEMF for the treatment of various central nervous system disorders
ADDITIONAL PROGRAMS:
Endonovo Therapeutics will initiate and fund both currently planned and all future clinical trials to evaluate the use of PEMF in the treatment of central nervous system disorders, including traumatic brain injury, post-concussion syndrome, stroke and multiple sclerosis.
ADDS NEW DEVICE WITH FDA CLEARANCE:
The PEMF assets additionally includes a portable, disposable PEMF device with a CE Mark and an FDA 510(k) clearance for the treatment of soft tissue injuries and post-surgical pain and edema in addition to medical reimbursement for the treatment of chronic wounds
NEW PRODUCT PROVIDING REVENUE:
Endonovo Therapeutics will begin the commercialization of the PEMF assets through licensing and joint venture agreements and the creation of various sales channels and distribution agreements.
ENLARGED PROGRAMS:
"We are adding clinical stage programs and expanding our pipeline of non-invasive electroceuticals into central nervous system disorders, strengthening our intellectual property, and adding market-ready products for the treatment of various soft tissue injuries, post-surgical pain and swelling, as well as chronic wounds," stated Mr. Collier.
UPLISTING OF STOCK TO A NATIONAL STOCK EXCHANGE:
"This acquisition represents a significant milestone for Endonovo and positions the company as the leader in bioelectronic medicine allowing for more favorable financing, uplisting the company's common stock onto a national stock exchange and providing the company a valuation comparable to other companies in the electrical stimulation/electroceuticals sector," concluded Mr. Collier, Endonovo CEO .
Endonovo today announced it has acquired the PEMF assets of Rio Grande Neurosciences, Inc. ("RGN" for $4.5 million and settled its lawsuit concerning RGN's termination of the binding letter agreement to acquire RGN dated July 8, 2016.
RGN paid $150,000 to Endonovo Therapeutics
Endonovo to Fund All Currently Planned and Future Clinical Trials for Traumatic Brain Injury, Post-Concussion Syndrome, Stroke and Other Central Nervous System Disorders
ADDITIONAL SHARE HOLDER BENEFITS:
Endonovo believes settling the case at this time is in the best interest of all parties, and its acquisition of RGN's PEMF assets could result in substantial benefit to its shareholders.
27 MORE PATENTS:
The PEMF assets includes a portfolio of intellectual property, including 27 issued patents with foreign patent protection covering the therapeutic use of PEMF for the treatment of various central nervous system disorders
ADDITIONAL PROGRAMS:
Endonovo Therapeutics will initiate and fund both currently planned and all future clinical trials to evaluate the use of PEMF in the treatment of central nervous system disorders, including traumatic brain injury, post-concussion syndrome, stroke and multiple sclerosis.
ADDS NEW DEVICE WITH FDA CLEARANCE:
The PEMF assets additionally includes a portable, disposable PEMF device with a CE Mark and an FDA 510(k) clearance for the treatment of soft tissue injuries and post-surgical pain and edema in addition to medical reimbursement for the treatment of chronic wounds
NEW PRODUCT PROVIDING REVENUE:
Endonovo Therapeutics will begin the commercialization of the PEMF assets through licensing and joint venture agreements and the creation of various sales channels and distribution agreements.
ENLARGED PROGRAMS:
"We are adding clinical stage programs and expanding our pipeline of non-invasive electroceuticals into central nervous system disorders, strengthening our intellectual property, and adding market-ready products for the treatment of various soft tissue injuries, post-surgical pain and swelling, as well as chronic wounds," stated Mr. Collier.
UPLISTING OF STOCK TO A NATIONAL STOCK EXCHANGE:
"This acquisition represents a significant milestone for Endonovo and positions the company as the leader in bioelectronic medicine allowing for more favorable financing, uplisting the company's common stock onto a national stock exchange and providing the company a valuation comparable to other companies in the electrical stimulation/electroceuticals sector," concluded Mr. Collier, Endonovo CEO .
4
